A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, DenmarkSpecial Reporting on:• VARSITY: A Double-Blind, Double-Dummy, Randomized Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis• Analyses of Data From the VISIBLE 1 and 2 Trials: Vedolizumab in Patients With Ulcerative Colitis or Crohn's Disease• Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib as an Induction Therapy in Adults With Moderately to Severely Active Ulcerative Colitis: Data From the U-ACHIEVE Study• Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results From the GEMINI LTS Study• Pediatric Crohn's Disease Adalimumab Level-Based Optimization Treatment (PAILOT) Randomized Controlled Trial• Maintenance Treatment With Mirikizumab, a P19-Directed IL-23 Antibody: 52-Week Results in Patients With Moderately to Severely Active Ulcerative Colitis• Real-World Effectiveness and Safety of Vedolizumab and Anti-TNF Therapy in Biologic-Naive Patients With Ulcerative Colitis or Crohn's Disease: Results From the EVOLVE Study• A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of a Targeted-Release Oral Cyclosporine Formulation in the Treatment of Mild to Moderate Ulcerative Colitis: Efficacy Results• Real-World Analyses of Patients With IBD Treated With VedolizumabPLUS Meeting Abstract Summaries With Expert Commentary by: Edward V. Loftus Jr, MDProfessor of MedicineDivision of Gastroenterology and HepatologyMayo ClinicRochester, Minnesota.